Value
3.4/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Fwd P/E | 1.0 |
| PEG | 6.9 |
| Analyst target | 9.0 |
- ▸Forward P/E: 122.0x
- ▸PEG: 1.02
INSM · Why this verdict
Why Insmed (INSM) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score5.5/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Analyst consensus implying roughly 83% price upside with a risk/reward ratio of nearly 11.8-to-1 reflects strong institutional conviction in this growth-stage biotech, but the business remains a substantial cash burner (free cash flow negative at 74% of revenue), concentrated in two products and a single supplier, and has missed earnings estimates in three of the last four quarters before a single recent beat.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock sits about 83% below analyst consensus price targets, and the defined risk/reward ratio stands at nearly 11.8-to-1 in the investor's favor—passing the asymmetry threshold by a wide margin and reflecting high institutional conviction in the long-term growth trajectory. Price targets | The stock closes at least 40% of the gap to the $177.86 target within 12 months as commercial execution improves and analyst confidence is maintained. | →Stable |
| CounterA wide spread to consensus targets in a cash-burning biotech often reflects speculative optionality rather than near-term operational delivery; three prior quarters of earnings misses suggest analysts' optimism has repeatedly outpaced execution. | ||
A Rule of 40 score of 156 places the company in the upper tier of growth efficiency, yet free cash flow is negative at 74% of revenue—meaning the growth engine is running well above the Rule-of-40 threshold while the business continues to consume cash at a substantial rate. Quality breakdown | Free cash flow losses narrow over the next 4 quarters, with the FCF-to-revenue burn rate improving from -74% toward -40% as commercial revenue scales. | →Stable |
| CounterA Rule of 40 score based heavily on growth rather than profitability can mask a business that cannot self-fund; if revenue growth decelerates before cash consumption falls, the runway shortens materially. | ||
A death cross has formed but momentum sits at the floor of the passing threshold (5.5 against a 5.0 minimum) in a recovery pattern, with on-balance volume rising yet the stock remaining below its 200-day moving average at a flat slope—technically mixed, not a confirmed uptrend. Momentum breakdown | The stock reclaims its 200-day moving average within 9 months and the slope turns positive, confirming the momentum recovery signal and reducing technical risk. | ↑Improving |
| CounterA death cross with a flat 200-day slope can reverse quickly in high-conviction growth biotechs; the rising on-balance volume and improving MACD suggest buyers are accumulating before the price confirmation arrives. | ||
Revenue is concentrated in two products (ARIKAYCE and BRINSUPRI) and commercial delivery depends on a single supplier (the Lamira device)—a configuration where any one regulatory, supply, or competitive disruption could materially impair the business. Bear case | Pipeline diversification progresses over 12 months, with at least one additional product advancing to late-stage trials, reducing dependence on two products. | ↑Improving |
| CounterConcentration in two commercial-stage products is typical for a growth-stage biotech in the build phase; the risk becomes material only if one product faces a clinical or regulatory setback, which is not the current base case. | ||
The stock sits about 83% below analyst consensus price targets, and the defined risk/reward ratio stands at nearly 11.8-to-1 in the investor's favor—passing the asymmetry threshold by a wide margin and reflecting high institutional conviction in the long-term growth trajectory.
→StablePrice targets
- Expectation
- The stock closes at least 40% of the gap to the $177.86 target within 12 months as commercial execution improves and analyst confidence is maintained.
CounterA wide spread to consensus targets in a cash-burning biotech often reflects speculative optionality rather than near-term operational delivery; three prior quarters of earnings misses suggest analysts' optimism has repeatedly outpaced execution.
A Rule of 40 score of 156 places the company in the upper tier of growth efficiency, yet free cash flow is negative at 74% of revenue—meaning the growth engine is running well above the Rule-of-40 threshold while the business continues to consume cash at a substantial rate.
→StableQuality breakdown
- Expectation
- Free cash flow losses narrow over the next 4 quarters, with the FCF-to-revenue burn rate improving from -74% toward -40% as commercial revenue scales.
CounterA Rule of 40 score based heavily on growth rather than profitability can mask a business that cannot self-fund; if revenue growth decelerates before cash consumption falls, the runway shortens materially.
A death cross has formed but momentum sits at the floor of the passing threshold (5.5 against a 5.0 minimum) in a recovery pattern, with on-balance volume rising yet the stock remaining below its 200-day moving average at a flat slope—technically mixed, not a confirmed uptrend.
↑ImprovingMomentum breakdown
- Expectation
- The stock reclaims its 200-day moving average within 9 months and the slope turns positive, confirming the momentum recovery signal and reducing technical risk.
CounterA death cross with a flat 200-day slope can reverse quickly in high-conviction growth biotechs; the rising on-balance volume and improving MACD suggest buyers are accumulating before the price confirmation arrives.
Revenue is concentrated in two products (ARIKAYCE and BRINSUPRI) and commercial delivery depends on a single supplier (the Lamira device)—a configuration where any one regulatory, supply, or competitive disruption could materially impair the business.
↑ImprovingBear case
- Expectation
- Pipeline diversification progresses over 12 months, with at least one additional product advancing to late-stage trials, reducing dependence on two products.
CounterConcentration in two commercial-stage products is typical for a growth-stage biotech in the build phase; the risk becomes material only if one product faces a clinical or regulatory setback, which is not the current base case.
Per-dimension breakdown
Quality
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.3 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Rule of 40 | 9.5 |
| Piotroski F | 5.6 |
- ▸Cash-burning: FCF -50% of revenue
- ▸Rule of 40: 246 (elite)
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| EPS growth | 10.0 |
Momentum
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 1.0 |
| Volume | 6.1 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -8.8%/30d — confirmed downtrend
Sentiment
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.0 |
| Analyst rating | 9.0 |
| Price target | 10.0 |
- ▸Analyst upside: 102%
Insider
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 3.1 |
| notable moves | 5.0 |
- ▸Notable insider selling — $39,197,298 (0.185% of mkt cap)
Peer rank
3.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.3 |
| quality rank | 0.8 |
| growth rank | 9.6 |
- ▸Industry growth leader
Technical
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.0 |
| support resistance | 8.2 |
| 52w position | 0.0 |
| gap | 6.0 |
Risk (lower is worse)
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.5 |
| days to cover | 5.7 |
| volatility | 5.2 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 8.1 |
| debt equity | 5.1 |
- ▸Elevated put/call: 14.40
- ▸High IV: 88%
- ▸Above max pain $50
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 9.4 |
| news activity | 8.0 |
- ▸Earnings concerns: 2B/2M
- ▸Earnings today
How the verdict was assembled
Engine trigger
Earnings today. Wait until post-earnings.
Engine technical detail
verdict_path:
L3:NEWS_BLOCK|ENTRY_STICKY:WITHIN_BANDPassed (7)
- MOMENTUM:6.3>=5.5
- ASYMMETRY:14.1>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- EARNINGS_PROXIMITY:0d<=7d
Warning (1)
- DEATH_CROSS:momentum=6.3>=5.0 recovering
Reward-to-Risk
14.09
Upside
+82.0%
Downside
5.8%
Sizing output
STARTER
SetupRecovery — Death cross but MACD improving, RSI 41
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -54% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
A recent news event triggered an L3 news-block on the verdict path. Trigger: Earnings today. Wait until post-earnings. The 10-dimension scores remain Growth at 10.0 (strongest), but EARNINGS_PROXIMITY:0d<=7d also fails — the news block is the proximate trigger, not the sole driver.
The strongest dimensions are Growth at 10.0, Sentiment at 8.0, and Momentum at 6.3; the weakest are Insider at 3.3, Value at 3.4, and Peer rank at 3.7. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 14.09 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Exceptional Upside Risk Reward
Trip ifAnalyst consensus price target falls below $130, compressing implied upside below 35%.
- P2Elite Growth Metric Vs Cash Burn
Trip ifFree cash flow turns positive (FCF-to-revenue ratio rises above 0%) for 2 consecutive quarters, resolving the cash burn concern.
- P3Momentum Recovery Not Yet Confirmed
Trip ifStock reclaims its 200-day moving average and RSI rises above 55 for 4 consecutive weeks, confirming the momentum recovery.
- P4Product Supplier Concentration Risk
Trip ifEither ARIKAYCE or BRINSUPRI receives a negative regulatory action or label restriction affecting commercial availability, sending the stock below $90.64.